Last reviewed · How we verify

Lidocaine 4%

Rigshospitalet, Denmark · FDA-approved active Small molecule Quality 5/100

Lidocaine 4% is a Amide Local Anesthetic [EPC] Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved. Also known as: Lidocaine Pain Relief Patch, Xylocaine, Liquid Lidocaine, LMX4.

At a glance

Generic nameLidocaine 4%
Also known asLidocaine Pain Relief Patch, Xylocaine, Liquid Lidocaine, LMX4
SponsorRigshospitalet, Denmark
Drug classAmide Local Anesthetic [EPC]
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lidocaine 4%

What is Lidocaine 4%?

Lidocaine 4% is a Amide Local Anesthetic [EPC] drug developed by Rigshospitalet, Denmark.

Who makes Lidocaine 4%?

Lidocaine 4% is developed and marketed by Rigshospitalet, Denmark (see full Rigshospitalet, Denmark pipeline at /company/rigshospitalet-denmark).

Is Lidocaine 4% also known as anything else?

Lidocaine 4% is also known as Lidocaine Pain Relief Patch, Xylocaine, Liquid Lidocaine, LMX4.

What drug class is Lidocaine 4% in?

Lidocaine 4% belongs to the Amide Local Anesthetic [EPC] class. See all Amide Local Anesthetic [EPC] drugs at /class/amide-local-anesthetic-epc.

What development phase is Lidocaine 4% in?

Lidocaine 4% is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing